SEC Filing Summary: Form 13F-HR
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Regeneron Pharmaceuticals, Inc., an institutional investment manager, for the quarter ended March 31, 2026. The report was signed by Leonard Brooks, Senior Vice President and Treasurer, on May 8, 2026. As a 13F filing, this document discloses the equity securities held by the manager rather than the operating financial results of Regeneron Pharmaceuticals itself.
Key Financial Metrics
The filing provides aggregate data regarding the manager's reported holdings:
- Total Value of Reported Holdings: $47,884,476
- Total Number of Holdings Entries: 2
- Number of Other Included Managers: 0
Note: This filing does not contain revenue, profit, cash flow, margins, debt, or liquidity metrics for Regeneron Pharmaceuticals, Inc. as an operating company. It only reflects the value of external equity investments managed by the firm.
Material Changes
The filing text does not provide comparative data for the prior period (December 31, 2025) to determine material changes in holdings or value. The report indicates it is a standard holdings report, not an amendment adding new entries or restating prior data.
Guidance, Outlook, and Risks
Form 13F filings are statutory disclosures of holdings and do not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Key Facts for Investor Verification
- Verify the specific identity of the two equity holdings comprising the $47.9 million portfolio, as the provided text lists only the aggregate count and value.
- Confirm whether this filing represents the entirety of Regeneron Pharmaceuticals' investment portfolio or if other managers report additional holdings (the filing states "NONE" for other included managers).
- Understand that this document reflects Regeneron's role as an investment manager, not its pharmaceutical business performance.